Robert A. Van Hulst

Prof. Dr. Robert A. Van Hulst

Department of Anesthesiology, Amsterdam UMC, Location AMC, 1100 DD Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
SWSilke de Wolde
Silke de Wolde
RHRick H. Hulskes
Rick H. Hulskes
RWRobert Weenink
Robert Weenink
MHMarkus W. Hollmann
Markus W. Hollmann
Robert A. Van HulstRobert A. Van Hulst
Robert A. Van Hulst
Hyperbaric oxygen therapy (HBOT) is commonly used as treatment in several diseases, such as non-healing chronic wounds, late radiation injuries and carbon monoxide poisoning. Ongoing research into HBOT has shown that preconditioning for surgery is a potential new treatment application, which may reduce complication rates and hospital stay. In this review, the effect of HBOT on oxidative stress, inflammation and angiogenesis is investigated to better understand the potential mechanisms underlying preconditioning for surgery using HBOT. A systematic search was conducted to retrieve studies measuring markers of oxidative stress, inflammation, or angiogenesis in humans. Analysis of the included studies showed that HBOT-induced oxidative stress reduces the concentrations of pro-inflammatory acute phase proteins, interleukins and cytokines and increases growth factors and other pro-angiogenesis cytokines. Several articles only noted this surge after the first HBOT session or for a short duration after each session. The anti-inflammatory status following HBOT may be mediated by hyperoxia interfering with NF-κB and IκBα. Further research into the effect of HBOT on inflammation and angiogenesis is needed to determine the implications of these findings for clinical practice.

12 July 2023 in Critical Care
Verified
Journal Article
Open access
PDF file
RFRaoul A. Fakkert
Raoul A. Fakkert
NKNoa Karlas
Noa Karlas
PSPatrick Schober
Patrick Schober
NHNina Hauck-Weber
Nina Hauck-Weber
Benedikt PreckelBenedikt Preckel
Benedikt Preckel
RWRobert Weenink
Robert Weenink
Background: Iatrogenic cerebral arterial gas embolism (CAGE) caused by invasive medical procedures may be treated with hyperbaric oxygen therapy (HBOT). Previous studies suggested that initiation of HBOT within 6–8 h is associated with higher probability of favorable outcome, when compared to time-to-HBOT beyond 8 h. We performed a group level and individual patient level meta-analysis of observational studies, to evaluate the relationship between time-to-HBOT and outcome after iatrogenic CAGE. Methods: We systematically searched for studies reporting on time-to-HBOT and outcome in patients with iatrogenic CAGE. On group level, we meta-analyzed the differences between median time-to-HBOT in patients with favorable versus unfavorable outcome. On individual patient level, we analyzed the relationship between time-to-HBOT and probability of favorable outcome in a generalized linear mixed effects model. Results: Group level meta-analysis (ten studies, 263 patients) shows that patients with favorable outcome were treated with HBOT 2.4 h (95% CI 0.6–9.7) earlier than patients with unfavorable outcome. The generalized linear mixed effects model (eight studies, 126 patients) shows a significant relationship between time-to-HBOT and probability of favorable outcome (p = 0.013) that remains significant after correcting for severity of manifestations (p = 0.041). Probability of favorable outcome decreases from approximately 65% when HBOT is started immediately, to 30% when HBOT is delayed for 15 h. Conclusions: Increased time-to-HBOT is associated with decreased probability of favorable outcome in iatrogenic CAGE. This suggests that early initiation of HBOT in iatrogenic CAGE is of vital importance.

28 February 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RWRobert Weenink
Robert Weenink
SJStijn W. de Jonge
Stijn W. de Jonge
Robert A. Van HulstRobert A. Van Hulst
Robert A. Van Hulst
Thijs WingelaarThijs Wingelaar
Thijs Wingelaar
POPieter-Jan van Ooij
Pieter-Jan van Ooij
MHMarkus W. Hollmann
Markus W. Hollmann
The use of an inspiratory oxygen fraction of 0.80 during surgery is a topic of ongoing debate. Opponents claim that increased oxidative stress, atelectasis, and impaired oxygen delivery due to hyperoxic vasoconstriction are detrimental. Proponents point to the beneficial effects on the incidence of surgical site infections and postoperative nausea and vomiting. Also, hyperoxygenation is thought to extend the safety margin in case of acute intraoperative emergencies. This review provides a comprehensive risk-benefit analysis for the use of perioperative hyperoxia in noncritically ill adults based on clinical evidence and supported by physiological deduction where needed. Data from the field of hyperbaric medicine, as a model of extreme hyperoxygenation, are extrapolated to the perioperative setting. We ultimately conclude that current evidence is in favour of hyperoxia in noncritically ill intubated adult surgical patients.

11 May 2021 in Journal of Otology
Verified
Journal Article
Open access
ABAhmed Bayoumy Bayoumy
Ahmed Bayoumy Bayoumy
RWRobert Weenink
Robert Weenink
EVE.L. van der Veen
E.L. van der Veen
FBF.S. Besseling-Hansen
F.S. Besseling-Hansen
AHA.D.M. Hoedemaeker
A.D.M. Hoedemaeker
JRJ.A. de Ru
J.A. de Ru
Background: Acute acoustic trauma (AAT) is an acute hearing impairment caused by intense noise-impact. The current management strategy for AAT with substantial hearing loss in the Dutch military is the combination therapy with corticosteroids and hyperbaric oxygen therapy (HBOT). In a previous study, early initiation of the combination therapy was associated with better outcomes. Therefore, we performed a new analysis to assess the difference in hearing outcome between patients in whom combination therapy was started within two days, versus after more than two days. Methods: A retrospective analysis was performed on military patients diagnosed with AAT with substantial hearing loss who presented between February 2018 and March 2020. Absolute and relative hearing improvement between first and last audiograms were calculated for all affected frequencies (defined as loss of >= 20 dB on initial audiogram). We also determined the amount of patients who recovered to the level of Dutch military requirement, and performed speech discrimination tests. Results: In this analysis, 30 male patients (49 ears) with AAT were included. The median age was 24.5 years (IQR 23-29). The median time to initiation of therapy with corticosteroids and HBOT were one and two days, respectively. HBOT was started within two days in 31 ears, and after more than two days in 18 ears. The mean absolute and relative hearing gains were 18.8 dB (SD 14.6) and 46.8% (SD 31.3) on all affected frequencies. The 100% discrimination/speech perception level improved from 64.0 dB to 51.7 dB (gain 12.3 dB +/- 14.1). There was significantly more improvement in absolute and relative hearing improvement when HBOT was started in <= 2 days, compared to >2 days. Conclusion: Our analysis shows results in favor of early initiation (<= 2 days) of the combination treatment of HBOT and corticosteroids in patients with AAT. (C) 2021 PLA General Hospital Department of Otolaryngology Head and Neck Surgery. Production and hosting by Elsevier (Singapore) Pte Ltd.

30 July 2020 in Techniques in Coloproctology
Verified
Journal Article
Open access
PDF file
RWRobert Weenink
Robert Weenink
MKM. Kloosterman
M. Kloosterman
RHR. Hompes
R. Hompes
PZPatricia Zondervan
Patricia Zondervan
HBH. P. Beerlage
H. P. Beerlage
Robert A. Van HulstRobert A. Van Hulst
Robert A. Van Hulst
Background: Surgical procedures that use insufflation carry a risk of gas embolism, which is considered relatively harmless because of the high solubility of carbon dioxide. However, an in vitro study suggested that valveless insufflation devices may entrain non-medical room air into the surgical cavity. Our aim was to verify if this occurs in actual surgical procedures. Methods: The oxygen percentage in the pneumoperitoneum or pneumorectum/pneumopelvis of eight patients operated with use of the AirSeal® was continuously measured, to determine the percentage of air in the total volume of the surgical cavity. Results: Basal air percentage in the surgical cavity was 0–5%. During suctioning from the operative field air percentage increased to 45–65%. Conclusions: The AirSeal® valveless insufflation device maintains optimal distension of the surgical cavity not only by insufflating carbon dioxide, but also by entraining room air, especially during suctioning from the operative field. This may theoretically lead to air embolism in patients operated on with this device.

21 February 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
FJFeiko Jaime Michiel de Jong
Feiko Jaime Michiel de Jong
Thijs WingelaarThijs Wingelaar
Thijs Wingelaar
PBPaul Brinkman
Paul Brinkman
POPieter Jan van Ooij
Pieter Jan van Ooij
Anke H. Maitland-van der ZeeAnke H. Maitland-van der Zee
Anke H. Maitland-van der Zee
Robert A. Van HulstRobert A. Van Hulst
Robert A. Van Hulst
The COMEX-30 hyperbaric treatment table is used to manage decompression sickness in divers but may result in pulmonary oxygen toxicity (POT). Volatile organic compounds (VOCs) in exhaled breath are early markers of hyperoxic stress that may be linked to POT. The present study assessed whether VOCs following COMEX-30 treatment are early markers of hyperoxic stress and/or POT in ten healthy, nonsmoking volunteers. Because more oxygen is inhaled during COMEX-30 treatment than with other treatment tables, this study hypothesized that VOCs exhaled following COMEX-30 treatment are indicators of POT. Breath samples were collected before and 0.5, 2, and 4 h after COMEX-30 treatment. All subjects were followed-up for signs of POT or other symptoms. Nine compounds were identified, with four (nonanal, decanal, ethyl acetate, and tridecane) increasing 33–500% in intensity from before to after COMEX-30 treatment. Seven subjects reported pulmonary symptoms, five reported out-of-proportion tiredness and transient ear fullness, and four had signs of mild dehydration. All VOCs identified following COMEX-30 treatment have been associated with inflammatory responses or pulmonary diseases, such as asthma or lung cancer. Because most subjects reported transient pulmonary symptoms reflecting early-stage POT, the identified VOCs are likely markers of POT, not just hyperbaric hyperoxic exposure.